Pre-made Vilobelimab benchmark antibody ( Whole mAb, anti-C5/CO5 therapeutic antibody, Anti-CPAMD4/ECLZB Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Vilobelimab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-621-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Vilobelimab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody
INN Name	Vilobelimab
Target	CO5
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	InflaRX
Conditions Approved	na
Conditions Active	Hidradenitis suppurativa;Inflammation;COVID-19;Microscopic polyangiitis;Pyoderma gangrenosum;Sepsis;Systemic inflammatory response syndrome;Squamous cell cancer
Conditions Discontinued	Inflammation
Development Tech	na